Popular weight loss drugs are so pricey that many may shell out hundreds or even thousands of dollars on them. Some ...

If Medicare were to start covering popular weight loss drugs such as Wegovy and Zepbound, it could increase federal spending ...

Fewer than 20% of large employers are covering GLP-1 weight loss drugs like Ozempic, a new KFF analysis shows.

The market for injectable weight loss medications has experienced rapid growth. Goldman Sachs Research predicts the global ...

Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the ...

Allowing Medicare to cover popular weight loss drugs such as Wegovy and Zepbound could increase federal spending by billions ...

Only a fifth of large U.S. companies cover pricey GLP-1 weight-loss drugs like Wegovy and Zepbound in their health insurance ...

When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies ...

With the resolution, compounding pharmacies are no longer able to produce tirzepatide. And the FDA highlighted the point to ...

Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...

A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such ...